文献速递艾滋病与性传播感染

非洲儿童中替诺福韦艾拉酚胺富马酸盐与替诺福韦联合多替拉韦或增效蛋白酶抑制剂的首次药代动力学数据:CHAPAS-4试验子研究

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
PubMed 文献 · Clin Infect Dis · 2023-01-01

该子研究纳入104名3-15岁一线抗逆转录病毒治疗失败的非洲HIV感染儿童,随机接受恩曲他滨/替诺福韦艾拉酚胺(TAF)或标准核苷类逆转录酶抑制剂组合,联合多替拉韦、阿扎那韦/利托那韦、达芦那韦/利托那韦或洛匹那韦/利托那韦。按WHO推荐体重带给药后,TAF与多替拉韦、达芦那韦/利托那韦或洛匹那韦/利托那韦联用时AUC与成人参考值相当,与阿扎那韦/利托那韦联用时TAF AUC升高;各组合替诺福韦暴露均低于成人参考值。

要点

  • TAF联合多替拉韦、达芦那韦/利托那韦或洛匹那韦/利托那韦时AUC与成人参考值相当。
  • TAF联合阿扎那韦/利托那韦时TAF AUClast升至511.4 ng·h/mL。
  • 各组合替诺福韦AUCtau和Cmax均低于成人参考值。

核心结论

  • 儿童按WHO推荐体重带接受TAF联合增效蛋白酶抑制剂或多替拉韦,可提供此前在成人中证实耐受良好且有效的TAF和替诺福韦浓度。
  • 这些数据为非洲儿童使用这些组合提供了首个证据。

研究设计与样本

  • CHAPAS-4试验子研究,纳入3-15岁一线抗逆转录病毒治疗失败的HIV感染非洲儿童。
  • 随机接受恩曲他滨/TAF或标准核苷类逆转录酶抑制剂组合,联合多替拉韦、阿扎那韦/利托那韦、达芦那韦/利托那韦或洛匹那韦/利托那韦。
  • 恩曲他滨/TAF按WHO推荐体重带每日给药:体重14至<25 kg为120/15 mg,体重≥25 kg为200/25 mg。
  • 稳态时采集8-9份血样构建药代动力学曲线,共分析104名儿童的药代动力学结果。

主要发现

  • TAF联合多替拉韦(n=18)时AUClast几何均值(CV%)为284.5(79)ng·h/mL。
  • TAF联合达芦那韦/利托那韦(n=34)时AUClast几何均值(CV%)为232.0(61)ng·h/mL。
  • TAF联合洛匹那韦/利托那韦(n=20)时AUClast几何均值(CV%)为210.2(98)ng·h/mL。
  • TAF联合阿扎那韦/利托那韦(n=32)时AUClast几何均值(CV%)升至511.4(68)ng·h/mL。
  • 各组合替诺福韦AUCtau和Cmax几何均值(CV%)均低于接受25 mg TAF联合增效蛋白酶抑制剂的成人参考值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the pharmacokinetics of tenofovir alafenamide fumarate (TAF) and tenofovir in a subset of African children enrolled in the CHAPAS-4 trial. METHODS: Children aged 3-15 years with human immunodeficiency virus infection failing first-line antiretroviral therapy were randomized to emtricitabine/TAF versus standard-of-care nucleoside reverse transcriptase inhibitor combination, plus dolutegravir, atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. Daily emtricitabine/TAF was dosed according to World Health Organization (WHO)-recommended weight bands: 120/15 mg in children weighing 14 to <25 kg and 200/25 mg in those weighing ≥25 kg. At steady state, 8-9 blood samples were taken to construct pharmacokinetic curves. Geometric mean (GM) area under the concentration-time curve (AUC) and the maximum concentration (Cmax) were calculated for TAF and tenofovir and compared to reference exposures in adults. RESULTS: Pharmacokinetic results from 104 children taking TAF were analyzed. GM (coefficient of variation [CV%]) TAF AUClast when combined with dolutegravir (n = 18), darunavir/ritonavir (n = 34), or lopinavir/ritonavir (n = 20) were 284.5 (79), 232.0 (61), and 210.2 (98) ng*hour/mL, respectively, and were comparable to adult reference values. When combined with atazanavir/ritonavir (n = 32), TAF AUClast increased to 511.4 (68) ng*hour/mL. For each combination, tenofovir GM (CV%) AUCtau and Cmax remained below reference values in adults taking 25 mg TAF with a boosted protease inhibitors. CONCLUSIONS: In children, TAF combined with boosted PIs or dolutegravir and dosed according to WHO-recommended weight bands provides TAF and tenofovir concentrations previously demonstrated to be well tolerated and effective in adults. These data provide the first evidence for use of these combinations in African children. CLINICAL TRIALS REGISTRATION: ISRCTN22964075.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Waalewijn H, Szubert AJ, Wasmann RE, et al. First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial. Clin Infect Dis. 2023. PMID: 37315296. doi:10.1093/cid/ciad267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。